Listenly

How much can plan sponsors save by redirecting chemotherapy patients to lower-cost, high-quality providers with direct contracts?

Answered at 12:00 in AH118 - Chemo, Cars, & Where Health Plan Savings May be Hiding, with Brian Cotter · The Astonishing Healthcare Podcast

— questions searchable right now

How much can plan sponsors save by redirecting chemotherapy patients to lower-cost, high-quality providers with direct contracts?

One plan sponsor implemented a transportation program moving members to a preferred medical center where chemotherapy prices were around 100% of Medicare, compared to local options priced at 500% and above Medicare. This strategy saved 80% on chemotherapy costs for every member successfully transported to the preferred provider.

Brian Cotter on The Astonishing Healthcare PodcastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

One plan sponsor implemented a transportation program moving members to a preferred medical center where chemotherapy prices were around 100% of Medicare, compared to local options priced at 500% and above Medicare.

Brian Cotter, Founder at Bright Spot Insights · AH118 - Chemo, Cars, & Where Health Plan Savings May be Hiding, with Brian Cotter · The Astonishing Healthcare Podcast · answer at 12:00

Key takeaways

  • One plan sponsor implemented a transportation program moving members to a preferred medical center where chemotherapy prices were around 100% of Medicare, compared to local options priced at 500% and above Medicare.

Quote to remember

“Assume the data is incorrect until proven otherwise. You need to work through the steps to validate the data before you can start digging in and understanding what price variation you see.”

— Brian Cotter

The full answer · about 1 min

One plan sponsor implemented a transportation program moving members to a preferred medical center where chemotherapy prices were around 100% of Medicare, compared to local options priced at 500% and above Medicare. This strategy saved 80% on chemotherapy costs for every member successfully transported to the preferred provider.

Key facts

  • Oxaliplatin ASP price dropped from $2,053 in 2012 to $9.40 in Q1 2026—a 99% reduction
  • One hospital listed oxaliplatin at $29,595 compared to Medicare reimbursement under $10
  • Specialty drug spend now represents 55-60% of pharmacy spend
  • Pharmacy spend represents 25-30% of total plan spend
  • 431 drugs had price drops between Q1 2025 and Q1 2026, with drops up to 99%

People, companies and topics mentioned

Bright Spot InsightsMedicareASP (Average Sales Price)J code (J9263 for oxaliplatin/Eloxatin)Oxaliplatin (Eloxatan)Specialty drugs (oncology)Price transparency dataMedical benefit

More answers from this episode

 ·  All answers from The Astonishing Healthcare Podcast →
—
—
0:00
0:00